Foundayo (Orforglipron): the First GLP-1 Pill for Weight

Foundayo is the first GLP-1 pill approved for weight management, and it does something no injection can: you swallow it once a day, with or without food, and there is no needle involved at any point. Eli Lilly got it approved on 1 April 2026.^[1] At its maximum dose it produced 11.1% weight loss over 72 weeks.^[2]

Both halves of that matter. It is genuinely more convenient than anything else approved for this. It is also, on the numbers published so far, less effective than the injections it is being compared to — and that trade is the whole decision.

What was actually approved

Who it is for, per the label: adults carrying obesity, or adults carrying excess weight who also have a condition connected to it. The approval covers both losing the weight and keeping it off over the long term, and it is explicitly conditioned on diet and exercise running alongside — the drug is approved as part of a program, not instead of one.^[2] Stacking it with a second GLP-1 is not recommended.

How well it works

Two placebo-controlled trials of 72 weeks each support the approval, and they were split by diabetes status. Trial 1 took 3,127 participants and deliberately excluded anyone with type 2 diabetes; Trial 2 enrolled the people Trial 1 turned away.^[2] Running them separately is what makes the results readable, because diabetes changes how much weight these drugs shift.

Averages hide the spread, so the responder figure is the more useful one: on the top dose in Trial 1, 71.5% cleared the 5% threshold that counts as a clinically meaningful loss, where 26.8% did so on placebo.^[2] The dose response is clean — more drug, more effect — and the benefit held across age, sex, race, ethnicity, starting BMI and blood sugar status.

Against the injections

With that caveat honored, the shape is hard to miss: the pill lands below both injections. If you want the largest average weight loss on the market, the evidence still points at tirzepatide. If you will not or cannot inject, this is the first approved option that respects that — and 11.1% is a real clinical result, not a consolation.

The boxed warning, read carefully

Foundayo carries the same boxed warning about thyroid C-cell tumors as the rest of the GLP-1 class, and it is worth reading rather than pattern-matching, because the label says something unusual.

“Orforglipron is not pharmacologically active in rats or mice and did not produce tumors in rodents… While orforglipron is pharmacologically active at the human GLP-1 receptor, the human relevance of GLP-1 receptor-dependent thyroid C-cell tumors observed in rodents has not been determined.”^[2]

— FDA label, FOUNDAYO — Boxed Warning

The rodent tumors that generated this warning for the class were not produced by this molecule — it is not active in those species, so the experiment could not have produced them either way. The warning is retained because the human question behind it remains open, not because orforglipron failed a test. Two groups are ruled out entirely regardless: anyone whose own history or whose family’s includes medullary thyroid carcinoma, and anyone with MEN 2.

The interactions that are new

⛔ This is where being a small molecule cuts the other way, and it is the part most likely to be skipped. Injectable GLP-1s are peptides and largely sidestep liver enzyme interactions. Orforglipron does not — it runs through CYP3A4, so other drugs change its levels and it changes theirs.^[2]

• Strong CYP3A4 inhibitors — your ceiling becomes 9 mg a day rather than 17.2 mg. Ones that also block OATP1B should not be combined with it at all.
• Strong CYP3A4 inducers — avoid. With moderate ones, the drug may simply work less well, so response needs watching and the dose may have to climb.
• Simvastatin — capped at 20 mg once daily while you are on it.
• Oral contraceptives — the label directs users onto a non-oral method, or onto an added barrier method. ★ Easy to miss, and expensive to miss.
• Anything else you swallow — gastric emptying slows, and that can change how another tablet is taken up.

What people actually reported

Reported in at least 5% of people taking it: nausea, constipation, diarrhea, vomiting, dyspepsia, abdominal pain, headache, abdominal distension, fatigue, eructation, gastroesophageal reflux, flatulence — and hair loss.^[2] Nausea ran 26–35% across the doses against 10% on placebo, and 5% of people stopped the drug because of gastrointestinal effects.

The label also warns on acute pancreatitis, severe gastrointestinal reactions (not recommended with severe gastroparesis), acute kidney injury from volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, hypersensitivity reactions, diabetic retinopathy progression, and acute gallbladder disease. Our pages on hair and muscle loss and pancreatitis and gallbladder risk go into those two in depth.

What it costs, and what it does not cost

Four sellers in this register currently list it: Found at $149 a month, ShedRx at $149, Sesame Care at $149 and Maximus at $199.99. That is a sample of four rather than a market, so treat it as a starting read rather than a median — we do not publish aggregate statistics below five recorded prices.

Two things worth knowing beyond the cash price. Foundayo is one of the drugs covered under the Medicare GLP-1 Bridge, which means a $50 monthly copay for eligible beneficiaries. And there is no compounded version of it, nor should there be: it is a new, on-patent, commercially available drug with no shortage, so anything sold to you as compounded orforglipron is not a legitimate compounded product. Our guide to which GLP-1s can be compounded explains why that line exists.

Common questions